Global Medical REIT Inc.
GMRE-PA$398M
Small CapNASDAQBiotechnology🇺🇸North America26 employees
Drugs in Pipeline
8
Phase 3 Programs
4
Upcoming Catalysts
2
Next Catalyst
Jun 30, 2026
11wMarket Overview
Stock performance and key metrics
GMRE-PA News
Catalyst Timeline
2 upcoming, 0 past
Drug Pipeline
Fezolinetant
Hot Flashes
33525
Tinea Pedis
Setidegrasib
Pancreatic Cancer
Enzalutamide
Metastatic Hormone Sensitive Prostate Cancer
GBT440
Sickle Cell Disease
peficitinib
Arthritis, Rheumatoid
ASP0113
Kidney Transplantation Cytomegalovirus (CMV) Negative Recipients
gilteritinib
Acute Myeloid Leukemia (AML)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Fezolinetant | Phase 3 | Hot Flashes | - | - |
33525 | Phase 3 | Tinea Pedis | - | - |
Setidegrasib | Phase 3 | Pancreatic Cancer | - | - |
Enzalutamide | Phase 3 | Metastatic Hormone Sensitive Prostate Cancer | - | - |
GBT440 | Phase 2 | Sickle Cell Disease | - | - |
peficitinib | Phase 2 | Arthritis, Rheumatoid | - | - |
ASP0113 | Phase 2 | Kidney Transplantation Cytomegalovirus (CMV) Negative Recipients | - | - |
gilteritinib | Phase 2 | Acute Myeloid Leukemia (AML) | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply